Latest:
Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer
Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Albiruni Ryan Abdul Razak, MRCP, MBBCh
Latest:
Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma
Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.
Chandrikha Chandrasekharan, MBBS
Latest:
AE Management of Cabozantinib
Panelists discuss how managing cabozantinib’s adverse effects requires proactive patient counseling about expected dose reductions, aggressive supportive care for manageable toxicities like hypertension and diarrhea, frequent early monitoring, and recognition that the median effective dose (40 mg) is lower than the starting dose (60 mg).
Andreana N. Holowatyj, PhD, MSCI
Latest:
Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer Susceptibility
Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.
John Allan, MD, Weill Cornell Medicine
Latest:
Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes
Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.
Joshua Abrahan, BSN, RN
Latest:
Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
Experts discuss their combined experience with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other immunotoxicities post chimeric antigen receptor (CAR) T-cell therapy, whether Moffitt Cancer Center implements a standardized protocol to address and resolve cell therapy–associated immunotoxicities, how interventions are modified across grades of severity, and the use of prophylactic strategies to mitigate treatment-related adverse events as well as the roles of the multidisciplinary team in patient monitoring during the initial 30 days and the longer-term postinfusion period.
Professor Timothy Elliott
Professor Timothy Elliott is the Kidani Professor of Immuno-oncology in the Nuffield Department of Medicine at the University of Oxford
Latest:
Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott
Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.